Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease.
作者:
主题词
成年人(Adult);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);1-脱氧野尻霉素(1-Deoxynojirimycin);α葡糖苷酶类(alpha-Glucosidases);药物疗法, 联合(Drug Therapy, Combination);糖原贮积病Ⅱ型(Glycogen Storage Disease Type II);治疗结果(Treatment Outcome)
DOI
10.1007/s00415-024-12843-x
PMID
39775064
发布时间
2025-02-05
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文